Etidronate for the the neurotologic symptoms of otosclerosis: preliminary study.
The efficacy of etidronate, a bisphosphonate, was assessed as a treatment for the inner ear symptoms of otosclerosis in a retrospective case review of 896 patients diagnosed with otosclerosis, with primary complaints of dizziness, hearing loss, tinnitus or Meniere's syndrome. The diagnosis of otosclerosis was based on small-pixel computed tomography of the temporal bones. Of the 896 patients placed on an etidronate protocol, 545 were followed for more than six months and were analyzed. The symptomatic response to etidronate, as well as audiologic and computerized rotary chair results were used in the assessment. Patients who were previously on sodium fluoride were separately analyzed. In this preliminary study etidronate appeared to be an effective treatment for the neurotologic symptoms of otosclerosis. Prospective blinded efficacy studies of the bisphosphonates in the treatment of otosclerosis should be undertaken.
Brookler
K H
KH
Neurotologic Associates, P.C., New York, New York 10021, USA.
Tanyeri
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D007758:Ear, Inner / Q000473:pathology; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010040:Otosclerosis / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies
D004164:Diphosphonates; D012968:Etidronic Acid